Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06784973 · ClinicalTrials.gov registry record · Phase 2
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT06784973 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 4 participants.
The verdict
NCT06784973, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this clinical study is to check if obeldesivir (ODV; GS-5245) is safe and well-tolerated by children with respiratory syncytial virus (RSV) infection. It will also look at how well ODV helps reduce the time it takes for children to feel better and for their RSV symptoms to improve. The primary objectives of this study are: a) to evaluate the safety and tolerability of ODV in pediatric participants with RSV infection; b) To evaluate the efficacy of ODV on time to alleviation of targeted RSV symptoms in pediatric participants with RSV infection.
Interventions
- DRUG Obeldesivir
- DRUG Obeldesivir Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2025-04-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06784973
The ClinicalTrials.gov registry entry for NCT06784973 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Obeldesivir is the first listed.
NCT06784973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06784973 about?
NCT06784973 is a clinical study titled "Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection". The goal of this clinical study is to check if obeldesivir (ODV; GS-5245) is safe and well-tolerated by children with respiratory syncytial virus (RSV) infection. It will also look at how well ODV helps reduce the time it takes for children to feel better and for their RSV symptoms to improve. The ...
What is the current status of trial NCT06784973?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2025-03-05. Estimated completion is 2025-04-16.
What interventions are being tested in trial NCT06784973?
The interventions under investigation include: Obeldesivir (DRUG), Obeldesivir Placebo (DRUG).
Who is sponsoring clinical trial NCT06784973?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.